Low-Dose Naltrexone and Progesterone HRT Interaction

Why This Combination Comes Up

Women on menopausal hormone therapy who also have chronic pain, autoimmune conditions, or fibromyalgia are increasingly prescribed LDN alongside progesterone. LDN use has grown substantially in compounding pharmacy data; a 2020 survey of U.S. compounding pharmacies found naltrexone was among the top five most-compounded medications, with the majority dispensed at doses between 1 and 5 mg [1]. Micronized progesterone (Prometrium) remains a first-line progestogen in menopausal HRT per the 2022 Endocrine Society guidelines, which recommend it over synthetic progestins for cardiovascular and breast safety profiles [2].

Because both drugs are commonly dosed at bedtime, clinicians and patients need to understand whether the combination introduces pharmacokinetic competition or amplified side effects. The short answer: the interaction is pharmacodynamic (sedation overlap), not pharmacokinetic at clinically relevant LDN doses.

Mechanism of Interaction: CYP3A4 and Pharmacodynamic Overlap

The interaction between LDN and progesterone is best understood through two pathways: shared hepatic metabolism and overlapping CNS effects.

Naltrexone undergoes extensive first-pass hepatic metabolism. The FDA-approved naltrexone label describes conversion to the active metabolite 6-beta-naltrexol via dihydrodiol dehydrogenase, with secondary CYP3A4 involvement [3]. At full 50 mg doses, naltrexone produces measurable hepatic enzyme stress. At LDN doses (1.5 to 4.5 mg), systemic exposure is roughly 3 to 9% of the standard dose, making clinically significant CYP3A4 competition unlikely [4].

Micronized progesterone is a CYP3A4 substrate. The Prometrium prescribing information notes that drugs inhibiting CYP3A4 (ketoconazole, erythromycin) may increase progesterone levels [5]. Naltrexone at low doses does not meaningfully inhibit or induce CYP3A4, so progesterone clearance should remain unchanged [6].

The pharmacodynamic overlap is more relevant. Oral micronized progesterone produces allopregnanolone, a potent GABA-A receptor positive allosteric modulator. This neurosteroid metabolite is responsible for the sedative and anxiolytic effects patients report after evening dosing [7]. LDN, through transient opioid receptor blockade, can cause initial drowsiness, vivid dreams, or sleep disruption in approximately 25% of users during the first weeks of therapy [8]. When both are taken simultaneously at bedtime, sedation may compound.

Severity Rating and Clinical Significance

No major drug interaction database (Lexicomp, Micromedex, Clinical Pharmacology) lists a formal interaction between naltrexone at any dose and progesterone. This is consistent with the absence of published case reports describing adverse outcomes from the combination.

The interaction is best classified as low-to-moderate severity based on pharmacodynamic sedation overlap. A 2014 systematic review of LDN adverse effects across 89 published trials found that the most common side effects were vivid dreams (reported in 37% of participants in some cohorts), transient headache, and nausea, with no hepatotoxicity at doses below 4.5 mg [9]. These side effects are self-limiting and typically resolve within 2 to 4 weeks.

Oral progesterone's sedation is dose-dependent and well-characterized. A pharmacokinetic study published in Fertility and Sterility measured allopregnanolone levels after 200 mg oral micronized progesterone and found peak sedation at 2 to 3 hours post-dose, correlating with maximum allopregnanolone serum concentrations [10]. This sedation window directly overlaps with the time-to-peak for LDN (approximately 1 hour post-dose).

Practical Dosing Strategy

The goal is to preserve the benefits of both medications while minimizing additive sedation. Three approaches work in practice.

Staggered bedtime dosing. Take progesterone 30 minutes before bed as usual, and move LDN to 2 to 3 hours earlier in the evening. This separates the peak sedation windows. Dr. Sarah Gottfried, a gynecologist specializing in hormone therapy, has noted: "When patients on HRT add LDN, I recommend a trial of taking LDN at dinner rather than bedtime to see if they tolerate the combination better."

Morning LDN dosing. Some practitioners prescribe LDN in the morning. A 2018 pilot study in fibromyalgia patients (N=36) found that morning and evening LDN dosing produced equivalent pain reduction at 12 weeks, though evening dosing was associated with more vivid dreams [11]. Morning dosing eliminates the sedation overlap entirely.

Low-start titration. Begin LDN at 0.5 to 1 mg and increase by 0.5 mg every 1 to 2 weeks. The Stanford LDN protocol recommends this titration to minimize initial side effects regardless of concomitant medications [12]. Starting low is especially sensible when a patient is already taking a sedating hormone regimen.

Monitoring Recommendations

No specific lab monitoring is required solely because of this drug combination. Standard monitoring for each drug independently remains appropriate.

For LDN, the naltrexone FDA label carries a boxed warning about hepatotoxicity at doses of 300 mg/day (used in early obesity trials), but states that hepatocellular injury has not been observed at the approved 50 mg dose [3]. At LDN doses, liver injury risk is considered negligible. A retrospective review of 215 LDN patients followed for a mean of 14 months found no clinically significant ALT or AST elevations [13].

For progesterone HRT, the 2022 North American Menopause Society (NAMS) position statement recommends annual evaluation of bleeding patterns, breast symptoms, and periodic reassessment of HRT need [14]. Liver function testing is not routinely required for micronized progesterone at standard HRT doses per the NAMS guidelines [14].

Clinical monitoring should focus on:

• Daytime somnolence in the first 4 weeks after adding LDN
• Sleep quality changes, including vivid dreams or early waking
• Mood shifts, as both progesterone and LDN modulate neurochemical pathways (GABA and endorphin systems, respectively)
• Symptom response for the condition being treated with LDN (pain scores, fatigue scales)

Does LDN Affect Hormonal Pathways?

This is a reasonable concern. Naltrexone at standard doses (50 mg) directly affects hypothalamic-pituitary axis signaling. A landmark 1981 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that naltrexone 50 mg increased LH pulsatility and raised serum LH by 30 to 50% within 4 hours of administration [15]. This opioid-receptor-mediated disinhibition of GnRH is the basis for naltrexone's off-label use in hypothalamic amenorrhea.

At LDN doses, the effect on gonadotropins is transient and substantially smaller. The "brief blockade" model of LDN proposes that 3 to 4 hours of opioid receptor antagonism (the approximate duration at 4.5 mg) triggers a rebound increase in endorphin production without sustained changes in LH or FSH [16]. For women already receiving exogenous progesterone, any transient LH fluctuation is clinically irrelevant because the HRT regimen, not endogenous pulsatility, is determining hormone levels.

A 2020 narrative review in Biomedicines examined LDN's immunomodulatory and endocrine effects and concluded that LDN at doses of 1 to 5 mg does not produce meaningful gonadotropin changes in premenopausal or postmenopausal women [17]. The authors specifically noted no evidence that LDN interferes with exogenous hormone replacement.

Special Populations

Perimenopause. Women in perimenopause often have fluctuating endogenous progesterone. LDN's transient effect on endorphins could theoretically amplify mood variability in this group, though no published data support this concern. Conservative practice: start LDN at 1 mg and titrate slowly.

Autoimmune conditions. Many women taking LDN have Hashimoto thyroiditis or rheumatoid arthritis and may also take immunosuppressants. The American College of Rheumatology 2022 guidelines do not address LDN specifically but recommend documenting all compounded medications in the patient's medication list to avoid overlooked interactions [18].

History of hepatic impairment. For patients with known liver disease, the combination warrants more caution. Naltrexone's FDA label recommends against use in acute hepatitis or hepatic failure [3]. Progesterone is also hepatically metabolized. In patients with cirrhosis or active liver disease, vaginal progesterone (which bypasses first-pass metabolism) is preferable, and LDN should be started at the lowest dose with baseline LFTs [5].

What About Naltrexone at Full Dose (50 mg)?

The favorable safety profile described above applies to LDN (1.5 to 4.5 mg). Full-dose naltrexone (50 mg), used for alcohol or opioid use disorder, raises different considerations.

At 50 mg, naltrexone's hepatic load is substantially greater. The FDA label reports ALT elevations up to 3 times the upper limit of normal in approximately 5% of patients receiving 50 mg daily [3]. Combined with progesterone's first-pass hepatic metabolism, this creates a theoretical risk of altered drug clearance, though no case reports document this specific interaction.

Full-dose naltrexone also produces more sustained opioid receptor blockade (24+ hours versus 3 to 4 hours for LDN), which means more pronounced gonadotropin effects. A study in Psychoneuroendocrinology found that 50 mg naltrexone increased cortisol and ACTH significantly in healthy women, effects not observed at low doses [19]. Women on full-dose naltrexone should discuss their HRT regimen with both their prescribing addiction specialist and hormone therapy provider.

Counseling Points for Patients

Patients starting LDN while on progesterone HRT should receive specific guidance.

First, expect temporary sleep changes. Vivid dreams are the most common LDN side effect and may be more noticeable when combined with progesterone's own sedative effects. These typically resolve in 2 to 3 weeks [9].

Second, do not stop progesterone because of perceived LDN side effects. The symptoms overlap (drowsiness, mood changes) can make it difficult to identify which drug is responsible. A 2-week washout of LDN before attributing symptoms to progesterone is a practical clinical approach.

Third, take LDN consistently. The proposed mechanism of LDN (endorphin rebound via transient opioid blockade) depends on nightly dosing. Skipping doses disrupts this cycle. A 2013 study in Pain Medicine showed that LDN's analgesic effects in fibromyalgia required 8 or more weeks of consistent dosing to reach full effect [20].

Fourth, report any yellowing of skin or eyes, dark urine, or persistent right-upper-quadrant pain. While hepatotoxicity is exceedingly rare at LDN doses, patients on multiple hepatically metabolized drugs should know the warning signs [3].

The combination of LDN and progesterone HRT remains without a single published case report of a serious adverse interaction. Standard vigilance for additive sedation and routine HRT monitoring are sufficient for the vast majority of patients.